New class of cancer drugs could work in colon cancers with genetic mutation
New class of cancer drugs could work in colon cancers with genetic mutation, U-M study finds — 15 percent of colorectal cancers have mutation that responds to PARP inhibitors – A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.